Hottest Stories: Symantec Corporation (NASDAQ:SYMC), Merck & Co. Inc. (NYSE:MRK), Johnson Controls (NYSE:JCI), Argos Therapeutics (NASDAQ:ARGS)

ExamWorks Group, Inc. (NYSE:EXAM) ended the last trading day at $27.02. Company weekly volatility is calculated as 4.36% and price to cash ratio as 8.91. ExamWorks Group, Inc. (NYSE:EXAM) showed a weekly performance of 0.45%.

On 19 January, ExamWorks Group, Inc. (NYSE:EXAM) announced the acquisition of Advanced Medical Reviews, Inc. (“AMR”) for an all cash purchase price of $30.0 million. Additionally, the AMR acquisition agreement contains an earnout provision providing the selling shareholders with additional cash payments of up to $9.8 million based on revenues to be generated from a new client over a 24-month period. ExamWorks funded the acquisition with cash on hand and borrowings under its existing senior secured revolving credit facility.

On 27 January, Symantec Corporation (NASDAQ:SYMC) shares decreased -0.08% and was closed at $19.22. SYMC EPS growth in last 5 year was 7.70%. Symantec Corporation (NASDAQ:SYMC) year to date (YTD) performance is -8.50%.

Symantec Corporation (NASDAQ:SYMC) and The Carlyle Group (NASDAQ: CG) announced that they expect to close Carlyle’s acquisition of Veritas on January 29, 2016, subject to the satisfaction of customary closing conditions. The closing was previously expected to take place on January 1, 2016.

Merck & Co. Inc. (NYSE:MRK) shares decreased -2.10% in last trading session and ended the day at $50.37. MRK Gross Margin is 63.70% and its has a return on assets of 10.50%. Merck & Co. Inc. (NYSE:MRK) quarterly performance is -3.98%.

Merck & Co. Inc. (NYSE:MRK) said that, it marketed cancer therapy Keytruda® (pembrolizumab) will be studied with Affimed Therapeutics’ cancer immunotherapy candidate AFM13 in a Phase IB trial assessing the combination in patients with Hodgkin’s lymphoma. The value of the clinical research collaboration was not disclosed by Affimed, which announced the partnership today.

Johnson Controls Inc. (NYSE:JCI) caters to the Consumer Goods space. It has a net profit margin of 4.20% and weekly performance is 1.30%. On the last day of trading company shares ended up at $35.13. Johnson Controls Inc. (NYSE:JCI) distance from 50-day simple moving average (SMA50) is -12.30%.

Johnson Controls Inc. (NYSE:JCI) agreed to acquire Ireland-based peer Tyco International Plc (TYC.N) in a $16.5 billion deal that will lower its tax bill, the companies said on Monday.

Argos Therapeutics, Inc. (NASDAQ:ARGS) caters to the Healthcare space. Its weekly performance is 27.01%. On the last day of trading company shares ended up at $2.92. Argos Therapeutics, Inc. (NASDAQ:ARGS) distance from 50-day simple moving average (SMA50) is -6.02%.

Argos Therapeutics, Inc. (NASDAQ:ARGS) has appointed Lee F. Allen, MD, PhD as chief medical officer. Allen previously served as chief medical officer for Spectrum Pharmaceuticals (SPPI). Additionally, the company also announced that on January 19, the compensation committee of the company’s Board of Directors approved an inducement grant of an option to purchase 300,000 shares of Argos’ common stock to Dr. Allen.